Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

424 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.
Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, Cook RS. Morrison MM, et al. Among authors: arteaga cl. J Clin Invest. 2013 Oct;123(10):4329-43. doi: 10.1172/JCI66764. Epub 2013 Sep 3. J Clin Invest. 2013. PMID: 23999432 Free PMC article.
Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL. Guix M, et al. Among authors: arteaga cl. J Clin Oncol. 2008 Feb 20;26(6):897-906. doi: 10.1200/JCO.2007.13.5939. Epub 2008 Jan 7. J Clin Oncol. 2008. PMID: 18180460 Clinical Trial.
Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, Nolting DD, Buck JR, Zhao P, Ansari MS, Baldwin RM, Gore JC, Schiff R, Arteaga CL, Manning HC. Shah C, et al. Among authors: arteaga cl. Clin Cancer Res. 2009 Jul 15;15(14):4712-21. doi: 10.1158/1078-0432.CCR-08-2635. Epub 2009 Jul 7. Clin Cancer Res. 2009. PMID: 19584166 Free PMC article.
Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.
Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, Arteaga CL. Miller TW, et al. Among authors: arteaga cl. Clin Cancer Res. 2009 Dec 1;15(23):7266-76. doi: 10.1158/1078-0432.CCR-09-1665. Epub 2009 Nov 24. Clin Cancer Res. 2009. PMID: 19934303 Free PMC article.
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.
Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, González-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, Kostler WJ, Lipton A, Bates M, Arteaga CL. Ghosh R, et al. Among authors: arteaga cl. Cancer Res. 2011 Mar 1;71(5):1871-82. doi: 10.1158/0008-5472.CAN-10-1872. Epub 2011 Feb 15. Cancer Res. 2011. PMID: 21324925 Free PMC article.
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, González-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL. Miller TW, et al. Among authors: arteaga cl. Clin Cancer Res. 2011 Apr 1;17(7):2024-34. doi: 10.1158/1078-0432.CCR-10-2567. Epub 2011 Feb 23. Clin Cancer Res. 2011. PMID: 21346144 Free PMC article.
424 results